Brief: Fusion Pharmaceuticals To Acquire Phase 2 Program For 225Ac-Psma I&T, A Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
13/02/2023 23:10
Feb 13 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS TO ACQUIRE PHASE 2 PROGRAM FOR
225AC-PSMA I&T, A RADIOPHARMACEUTICAL TARGETING METASTATIC
CASTRATE RESISTANT PROSTATE CANCER
* FUSION PHARMACEUTICALS INC - IN CONNECTION WITH
TRANSACTION,
FUSION ANNOUNCES $60.0 MILLION PRIVATE PLACEMENT FINANCING
* FUSION PHARMACEUTICALS INC - FOLLOWING CLOSING,
ALPHA-EMITTING
RADIOPHARMACEUTICAL BEING EVALUATED IN TATCIST TRIAL WILL BE
KNOWN AS FPI-2265.
Source text for Eikon: ID:nCNW0p5d9a
Further company coverage: FUSN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary